Sort
11,323 grants matching “glioblastoma”
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
$480,634James K Turkson · University Of Hawaii At Manoa · R01 · FY2016 · CA
Project 1: Spatial imaging of whole tumor genomics to understand glioblastoma formation and evolution
$480,584Joseph F Costello · University Of California, San Francisco · P01 · FY2024 · CA
Project 1: Spatial imaging of whole tumor genomics to understand glioblastoma formation and evolution
$480,584Joseph F Costello · University Of California, San Francisco · P01 · FY2025 · CA
EVALUATION OF 'CHEMOPREVENTIVE AGENTS BY IN VITRO SCREEN
$480,564Alion Science And Technology Corp · N01 · FY2000 · CN
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy
$480,392Noemi Andor · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2024 · CA
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma
$480,290Courtney A Miller · University Of Florida · R33 · FY2023 · NS
Cellular Transduction with Replication-Competent Retrovirus Vectors
$480,116Noriyuki Kasahara · University Of California Los Angeles · R01 · FY2007 · CA
Modeling the Glioblastoma Microenvironment to Uncover Progression Mechanisms and Therapeutic Targets
$480,014Daniel J Brat · Northwestern University At Chicago · R01 · FY2024 · CA
Mechanisms of Chemo/Radioresistance in Human Gliomas
$479,667Hugo W. Moser Res Inst Kennedy Krieger · R01 · FY2004 · NS
Targeting oncogenic dopamine receptor signaling in glioblastoma
$479,545Jeongwu Lee · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · CA
Radiation and Receptor Targeted RadioTheranostic Nanoparticles for Glioblastoma
$479,083Jay Fitzgerald Dorsey · University Of Pennsylvania · R01 · FY2016 · CA
Oncogenic Met Signaling in Urologic Malignancies
$478,765Donald Bottaro · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
$478,440James M Markert · University Of Alabama At Birmingham · R01 · FY2019 · CA
Targeting oncogenic dopamine receptor signaling in glioblastoma
$478,299Jeongwu Lee · Cleveland Clinic Lerner Com-Cwru · R01 · FY2019 · CA
Radiation and Receptor Targeted RadioTheranostic Nanoparticles for Glioblastoma
$478,279Jay Fitzgerald Dorsey · University Of Pennsylvania · R01 · FY2017 · CA
Dissecting the biology and consequence of circulating glioma cells
$478,223Jay Fitzgerald Dorsey · University Of Pennsylvania · R01 · FY2021 · CA
AHR-mediated immunosuppression in glioblastoma
$478,176Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2021 · ES
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
$478,120Albert Hong-Jae Kim · Washington University · R01 · FY2022 · NS
Quantitative Biomarker Imaging for Early Therapy Response Assessment in Cancer
$478,104James M Mountz · University Of Pittsburgh At Pittsburgh · U01 · FY2012 · CA
Endogenous synthesis of TRAIL by glioma cancer stem cells and resistance to TRAIL therapy
$478,001Candece L Gladson · Cleveland Clinic Lerner Com-Cwru · R56 · FY2023 · NS
Elucidating and targeting the molecular foundations of IDH mutant glioma
$477,777Timothy An-Thy Chan · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Radiation and Receptor Targeted RadioTheranostic Nanoparticles for Glioblastoma
$477,452Jay Fitzgerald Dorsey · University Of Pennsylvania · R01 · FY2018 · CA
A novel microfluidic device to predict brain cancer prognosis and response to therapy
$477,368Alfredo Quinones-Hinojosa · Mayo Clinic Jacksonville · R01 · FY2020 · CA
Project 2: Exploiting Labile Iron Pools for Improving NSCLC Therapy Using Pharmacological Ascorbate
$477,283Douglas Robert Spitz · University Of Iowa · P01 · FY2020 · CA
Project 2: Exploiting Labile Iron Pools for Improving NSCLC Therapy Using Pharmacological Ascorbate
$477,283Douglas Robert Spitz · University Of Iowa · P01 · FY2021 · CA